Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Net Cash Flow: 2010-2025

Historic Net Cash Flow for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -$1.8 million.

  • Lineage Cell Therapeutics' Net Cash Flow rose 5.68% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 422.35%. This contributed to the annual value of $10.5 million for FY2024, which is 56.98% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Net Cash Flow stood at -$1.8 million for Q3 2025, which was up 69.39% from -$5.9 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Net Cash Flow registered a high of $23.6 million during Q1 2021, and its lowest value of -$45.4 million during Q3 2022.
  • For the 3-year period, Lineage Cell Therapeutics' Net Cash Flow averaged around $2.7 million, with its median value being $2.1 million (2025).
  • Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' Net Cash Flow was 10,633.18% (2021), while the steepest drop was 6,853.33% (2021).
  • Lineage Cell Therapeutics' Net Cash Flow (Quarterly) stood at -$5.1 million in 2021, then crashed by 162.25% to -$13.3 million in 2022, then soared by 127.93% to $3.7 million in 2023, then skyrocketed by 385.80% to $18.0 million in 2024, then rose by 5.68% to -$1.8 million in 2025.
  • Its Net Cash Flow stands at -$1.8 million for Q3 2025, versus -$5.9 million for Q2 2025 and $2.1 million for Q1 2025.